N/A N=11 Nurse-Led Heart Failure Care Transition Intervention for African Americans: The Navigator Program
Heart Failure
Primary: Rehospitalization — 2; 6 hospital readmisions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
Parkinson's Disease
Primary: Severity of Participants Reporting Study-related Adverse Events at Each Dose Level — 1; 1; 1; 1.25 units on a scale
Phase 2 N=20 Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 80 mg
Phase 3 N=443 MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
Psoriasis · Plaque Type Psoriasis · Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16 — 89.7; 91.6 Percentage of Participants
N/A N=110 Safety and Performance Evaluation of the Calcivis System
Dental Caries
Primary: Number of Teeth Identified as Sound or Unsound by the Calcivis System That Were in Agreement With the Dentist's Assessment — 88; 78 teeth — p=<0.0001
N/A N=32 CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass
Heart Failure
Primary: Survival — 20 Participants
N/A N=541 Veterans Individual Placement and Support Towards Advancing Recovery
Posttraumatic Stress Disorder (PTSD)
Primary: Number of Participants Who Obtained and Maintained Competitive Employment for at Least 50% of the Active Follow-up Period — 105; 63 Participants — p=<0.001
Phase 3 N=167 Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
HIV-1 Infection
Primary: Percent Change From Baseline to Week 48 in Spine BMD — 2.237; -0.104 Percent change — p=<0.001
N/A N=147 Sonography Guided Transcervical Ablation of Uterine Fibroids
Menorrhagia
Primary: Percentage of Subjects With ≥ 50% Reduction in Menstrual Blood Loss as Assessed by Pictorial Blood Loss Assessment Chart (PBAC) — 64.8 percentage of participants
Phase 4 N=39 Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
Parkinson´s Disease
Primary: Change From Baseline to Visit 2 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Motor Score — -1.0; -5.3 Scores on a scale — p==0.134
Phase 4 N=21 The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Investigator Global Assessment Scale for Severity of Facial Acne — 0; 0; 11; 9 Participants
Phase 4 N=40 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters
Phase 2 N=89 A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
Geographic Atrophy
Primary: Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluorescence (FAF) at Week 24 — 0.614; 1.121; 1.049; 0.911 mm^2 — p=0.0428
Phase 1 N=6 MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants
N/A N=156 Stay Healthy In Nature Everyday: Family Nature Outings in a Low Income Population
Stress, Psychological · Social Isolation · Physical Activity
Primary: Change in Stress — -1.48; -1.83 units on a scale — p=0.6099